Infant Bacterial Therapeutics Abibtis A Clinical Stage Pharmaceutical Company Based In Stockholmswedenit Focuses On Developing Microbiome Targeted Therapies To Address Critical Medical Needs In Premature Infantsthe Company Specializes In Pharmaceutical Grade Probiotics And Biologics Aimed At Treating Rare Neonatal Diseasesparticularly Necrotizing Enterocolitisnecand Sepsis Ibt S Lead Productibp 9414Is A Phase 3 Probiotic Candidate Designed To Promote Gastrointestinal Development In Preterm Infantsthereby Reducing The Risks Of Nec And Sepsisthe Company Has Received Breakthrough Therapy Designation For This Product And Is Currently Conducting A Global Phase 3 Trialadditionallyibt Is Developing Ibp 1016 For Gastroschisis And Ibp 1118 For Retinopathy Of Prematurityboth Of Which Are In Various Stages Of Research And Developmentibt Collaborates With Clinical Research Organizations And Academic Institutions To Conduct Trials And Adheres To Strict Manufacturing Standards To Ensure The Safety And Efficacy Of Its Products
No conferences found for this company.
| Company Name | Infant Bacterial Therapeutics Ab |
| Country |
Sweden
|
| Address | N/A |
| Telephone | N/A |
| N/A |
